Live Market Updates
Latest Financial News
News Feed
1 articles
Personalized
Live Market Updates
Latest Financial News
positive
6 days agoDr Reddy’s Earnings Surpass Estimates With Double-Digit Revenue Growth
Dr Reddy’s Laboratories posted consolidated revenue of ₹16,250 crore for the September quarter, up 10% year on year, while profit after tax rose 14% to ₹1,437 crore, exceeding analyst projections. The company benefited from strong North America formulations, new launches, and margin improvement from cost controls. Management reiterated guidance for continued product diversification and R&D-driven expansion. Brokerages maintained positive outlooks citing consistent free cash generation and balance-sheet strength supporting shareholder returns despite pricing headwinds in select markets.
positive
6 days agoDr Reddy’s Earnings Surpass Estimates With Double-Digit Revenue Growth
Dr Reddy’s Laboratories posted consolidated revenue of ₹16,250 crore for the September quarter, up 10% year on year, while profit after tax rose 14% to ₹1,437 crore, exceeding analyst projections. The company benefited from strong North America formulations, new launches, and margin improvement from cost controls. Management reiterated guidance for continued product diversification and R&D-driven expansion. Brokerages maintained positive outlooks citing consistent free cash generation and balance-sheet strength supporting shareholder returns despite pricing headwinds in select markets.
positive
Dr Reddy’s Earnings Surpass Estimates With Double-Digit Revenue Growth
6 days ago
1 min read
77 words
Dr Reddy’s reported 10% revenue growth and 14% profit rise to ₹1,437 crore, beating estimates. Analysts cited product mix, cash flow strength, and cost efficiency as key drivers.
Dr Reddy’s Laboratories posted consolidated revenue of ₹16,250 crore for the September quarter, up 10% year on year, while profit after tax rose 14% to ₹1,437 crore, exceeding analyst projections. The company benefited from strong North America formulations, new launches, and margin improvement from cost controls. Management reiterated guidance for continued product diversification and R&D-driven expansion. Brokerages maintained positive outlooks citing consistent free cash generation and balance-sheet strength supporting shareholder returns despite pricing headwinds in select markets.
Dr Reddy’s Laboratories posted consolidated revenue of ₹16,250 crore for the September quarter, up 10% year on year, while profit after tax rose 14% to ₹1,437 crore, exceeding analyst projections. The company benefited from strong North America formulations, new launches, and margin improvement from cost controls. Management reiterated guidance for continued product diversification and R&D-driven expansion. Brokerages maintained positive outlooks citing consistent free cash generation and balance-sheet strength supporting shareholder returns despite pricing headwinds in select markets.
Companies:
Dr Reddy’s Laboratories
Tags:
stocks
earnings
stocks
earnings
pharma
India
Dr Reddy’s
Oct 24, 2025 • 15:32 IST